• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Lallo, Alice
    Frese, Kristopher K
    Morrow, C
    Szczepaniak S
    Gulati, Sakshi
    Schenk, Maximilian W
    Trapani, F
    Simms, N
    Galvin, Melanie
    Brown, Stewart
    Hodgkinson, Cassandra L
    Priest, Lynsey
    Hughes, A
    Lai, Z
    Cadogan, E
    Khandelwal, Garima
    Simpson, Kathryn L
    Miller, Crispin J
    Blackhall, Fiona H
    O'Connor, M
    Dive, Caroline
    Show allShow less
    Affiliation
    Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute
    Issue Date
    2018-06-25
    
    Metadata
    Show full item record
    Abstract
    Introduced in 1987, platinum-based chemotherapy remains standard of care for small cell lung cancer, a most aggressive, recalcitrant tumor. Prominent barriers to progress are paucity of tumor tissue to identify drug targets and patient relevant models to interrogate novel therapies. Following our development of circulating tumour cell patient-derived explants (CDX) as models that faithfully mirror patient disease, here we exploit CDX to examine new therapeutic options for small cell lung cancer.
    Citation
    The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer. 2018, Clin Cancer Res
    Journal
    Clinical Cancer Research
    URI
    http://hdl.handle.net/10541/621136
    DOI
    10.1158/1078-0432.CCR-17-2805
    PubMed ID
    29941481
    Type
    Article
    Language
    en
    ISSN
    1078-0432
    ae974a485f413a2113503eed53cd6c53
    10.1158/1078-0432.CCR-17-2805
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    • Authors: Lin X, Chen D, Zhang C, Zhang X, Li Z, Dong B, Gao J, Shen L
    • Issue date: 2018 Jun 28
    • Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    • Authors: Sen T, Tong P, Diao L, Li L, Fan Y, Hoff J, Heymach JV, Wang J, Byers LA
    • Issue date: 2017 Oct 15
    • Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
    • Authors: Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, Marsh KB, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA
    • Issue date: 2014 Oct 1
    • Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer.
    • Authors: Ha DH, Min A, Kim S, Jang H, Kim SH, Kim HJ, Ryu HS, Ku JL, Lee KH, Im SA
    • Issue date: 2020 Jun 18
    • The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    • Authors: Ma L, Bian X, Lin W
    • Issue date: 2020 Oct 17
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.